Cytovance Biologics Expands GMP Warehouse and Manufacturing Operations
Cytovance Biologics continues to work on the expansion of a manufacturing operations and GMP warehousing facility in Oklahoma.
Cytovance Biologics, a full-service contract manufacturer of mammalian and microbial biologics, continues to work on the expansion of a manufacturing operations and GMP warehousing facility. The multi-million dollar capital investment project is expected to be completed by June 2014.
Cytovance selected a construction site two miles north of its current campus in Oklahoma. The new facility, located at 3500 N. Santa Fe, will house 20,000 ft2 of climate controlled and monitored GMP warehouse space and 10,000 ft2 of space for existing and future manufacturing operations. Initially, this cleanroom space will be used for weighing and dispensing activities.
“Our new GMP warehouse will support incoming and outgoing supply-chain activities and provide full segregation between incoming, quarantine, and released materials,” explained Don Wuchterl, senior vice-president of manufacturing operations in a press release.
Source: Cytovance Biologics
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
